1. Home
  2. CYTH vs SHFS Comparison

CYTH vs SHFS Comparison

Compare CYTH & SHFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTH
  • SHFS
  • Stock Information
  • Founded
  • CYTH 1990
  • SHFS 2015
  • Country
  • CYTH United States
  • SHFS United States
  • Employees
  • CYTH N/A
  • SHFS N/A
  • Industry
  • CYTH Biotechnology: Pharmaceutical Preparations
  • SHFS Finance: Consumer Services
  • Sector
  • CYTH Health Care
  • SHFS Finance
  • Exchange
  • CYTH Nasdaq
  • SHFS Nasdaq
  • Market Cap
  • CYTH 20.4M
  • SHFS 22.4M
  • IPO Year
  • CYTH N/A
  • SHFS N/A
  • Fundamental
  • Price
  • CYTH $0.63
  • SHFS $0.42
  • Analyst Decision
  • CYTH Buy
  • SHFS
  • Analyst Count
  • CYTH 3
  • SHFS 0
  • Target Price
  • CYTH $0.95
  • SHFS N/A
  • AVG Volume (30 Days)
  • CYTH 43.6K
  • SHFS 192.3K
  • Earning Date
  • CYTH 11-14-2024
  • SHFS 11-12-2024
  • Dividend Yield
  • CYTH N/A
  • SHFS N/A
  • EPS Growth
  • CYTH N/A
  • SHFS N/A
  • EPS
  • CYTH N/A
  • SHFS 0.10
  • Revenue
  • CYTH $870,725.00
  • SHFS $15,658,629.00
  • Revenue This Year
  • CYTH N/A
  • SHFS N/A
  • Revenue Next Year
  • CYTH $24.49
  • SHFS N/A
  • P/E Ratio
  • CYTH N/A
  • SHFS $4.08
  • Revenue Growth
  • CYTH N/A
  • SHFS 7.78
  • 52 Week Low
  • CYTH $0.57
  • SHFS $0.30
  • 52 Week High
  • CYTH $2.12
  • SHFS $1.55
  • Technical
  • Relative Strength Index (RSI)
  • CYTH 46.82
  • SHFS 53.70
  • Support Level
  • CYTH $0.60
  • SHFS $0.37
  • Resistance Level
  • CYTH $0.69
  • SHFS $0.44
  • Average True Range (ATR)
  • CYTH 0.04
  • SHFS 0.04
  • MACD
  • CYTH 0.00
  • SHFS 0.00
  • Stochastic Oscillator
  • CYTH 50.00
  • SHFS 59.85

About CYTH Cyclo Therapeutics Inc.

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

About SHFS SHF Holdings Inc.

SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The group, through its financial institution clients, implements accountability, transparency, monitoring, reporting, and risk mitigation measures while meeting Bank Secrecy Act obligations in line with FinCEN guidance on cannabis-related businesses. Its services include Program Management Support, Customer Generation, Ongoing Program Auditing, and Compliance Monitoring among others.

Share on Social Networks: